[1] Shah R A, Kowdley K V. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 306-315.
[2] Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375(7): 631-643.
[3] John B V, Khakoo N S, Schwartz K B, et al. Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis with compensated cirrhosis[J]. Am J Gastroenterol, 2021, 116(9): 1913-1923.
[4] Harms M H, Van Buuren H R, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365.
[5] Liu C H, Bowlus C L. Treatment of primary biliary cholangitis: first-line and second-line therapies[J]. Clin Liver Dis, 2022, 26(4): 705-726.
[6] Hirschfield G M, Dyson J K, Alexander G J M, et al. The British society of gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67(9): 1568-1594.
[7] Hirschfield G M, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4): 751-761.e758.
[8] Trauner M, Nevens F, Shiffman M L, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study[J]. Lancet Gastroenterol Hepatol, 2019, 4(6): 445-453.
[9] Kowdley K V, Hirschfield G M, Coombs C, et al. COBALT: A confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls[J]. Am J Gastroenterol, 2025, 120(2): 390-400.
[10] Brookhart M A, Mayne T J, Coombs C, et al. Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): a trial emulation study design[J]. Hepatology, 2025, 81(6): 1647-1659.
[11] Hernán M A. Methods of public health research-strengthening causal inference from observational data[J]. N Engl J Med, 2021, 385(15): 1345-1348.
[12] Hernán M A, Robins J M. Using big data to emulate a target trial when a randomized trial is not available[J]. Am J Epidemiol, 2016, 183(8): 758-764.
[13] Hernán M A, Sauer B C, Hernández-Díaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses[J]. J Clin Epidemiol, 2016, 79: 70-75.
[14] Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis[J]. Hepatology, 2019, 70(3): 788-801.
[15 ] Schramm C, Wedemeyer H, Mason A, et al. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis[J]. JHEP Rep, 2022, 4(11): 100544.
[16] Akepati P R, Gochanour E M. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis[J]. Expert Opin Investig Drugs, 2024, 33(6): 627-638.
[17] Colapietro F, Gershwin M E, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales[J]. J Transl Autoimmun, 2023, 6: 100188.
[18] Ghonem N S, Auclair A M, Hemme C L, et al. Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol[J]. Clin Pharmacol Ther, 2020, 108(6): 1213-1223.
[19] Ding D, Guo G, Liu Y, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid[J]. Hepatol Commun, 2022, 6(12): 3487-3495.
[20 ] Ding D, Ren P, Guo G, et al. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid[J]. Gastroenterol Hepatol, 2023, 46(9): 692-701.
[21] Zhang Y, Chen K, Dai W, et al. Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: a meta-analysis[J]. Hepatol Res, 2015, 45(1): 48-58.
[22] Blair H A. Elafibranor: First Approval[J]. Drugs, 2024, 84(9): 1143-1148.
[23] Men X, Liu Y, Zhao H, et al. The treatment of primary biliary cholangitis: time for personalized medicine[J]. Clin Rev Allergy Immunol, 2025, 68(1): 63. |
